Overview

Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Status:
Completed

Trial end date:
2020-07-31

Target enrollment:

Participant gender:

Summary

A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction of anemia and maintenance of hemoglobin (Hb) in subjects with NDD-CKD

Phase:

Phase 3

Details

Lead Sponsor:

Akebia Therapeutics

Treatments:

Darbepoetin alfa